3 Obesity Drug Stocks to Buy ASAP – 6/28

New obesity figures were recently announced.

And they’re not so good.

According to the World Health Organization, obesity has more than doubled since 1990. In fact, global adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. And over 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity.

While that’s not great for millions of obese people around the world, it’s great news for biotech stocks getting caught up in the drug treatment boom.

Company: Eli Lilly (SYM: LLY)

Just look at Eli Lilly (SYM: LLY).

The company is seeing so much demand it’s spending $5.3 billion to make even more Mounjaro and Zepbound. According to The Wall Street Journal, Zepbound alone is generating more than 78,000 prescriptions every week in the U.S. No wonder shares of LLY exploded from a January low of about $580 to $901.26.

Financial Markets Daily

Little-known biotech company just had groundbreaking results from a study


As biotech stages a big comeback, one NYSE-traded company looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.

>> Get the stock symbol here <<

Other top stocks to keep an eye on include:

Company: Viking Therapeutics (SYM: VKTX)

The company reported that the injectable form of its treatment helped patients lose up to 13.1% of their weight after 13 weeks in Phase 2 trials. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. 

Two, thanks to Viking’s success in obesity drug trials, analysts at BTIG just reiterated a buy rating with a price target of $125 a share.

Oxford Club

AI’s Next Magnificent Seven


The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.

$1,000 in each turned into $1.18 million!

But the Man Who Called Nvidia at $1.10 Says “AI”s Next Magnificent Seven Could Do It Even Faster.”

He says $1,000 in these seven stocks could turn into $1 million+ in less than six years.

See His Breakdown of the Seven Stocks You Should Own Here.

Company: Altimmune (SYM: ALT)

Recent Phase 2 results showed that patients lost an average of 15.6% of their body weight at 48 weeks at the highest dose. The study also found that the treatment led to better lean mass preservation as compared to other similar weight loss treatments. 

“Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function,” CEO Vipin Garg said in a news release. “We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.”

Goldencrest Metals

Biden’s 44.6% Tax Bombshell: Protect Your Savings Now

Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025.

Click here to unlock your exclusive guide before it’s too late.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.